Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).By The Immune-Mediated Inflammatory Disease Forum

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).By The Immune-Mediated Inflammatory Disease Forum

Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.…

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 2 of EULAR 2025 (Thursday, June 12).By The Immune-Mediated Inflammatory Disease Forum

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 1 of EULAR 2025 (Wednesday, June 11).By The Immune-Mediated Inflammatory Disease Forum

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they guide you through what they are most looking forward to in RA, PsA, and axSpA at EULAR 2025, so that you can better plan your time at what will be a busy and exciting congress.By The Immune-Mediated Inflammatory Disease Forum

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and …

Join Professor Ian McInnes from the University of Glasgow, and Professors John Isaacs and Andrew Cope, as they discuss the latest AuToDeCRA study and what this means for rheumatology.By The Immune-Mediated Inflammatory Disease Forum

Join Professor Herve Bachelez and Professors Iain McInnes and Tim Orchard as they discuss the recent webinar hosted on the IMID Forum: “Advancing Patient Care Through an Interdisciplinary Approach to IMIDs”. Watch them discuss key highlights from the webinar including the clinical pathogenetic pathways, the Rheum-Derm-Gastro triggers and its implic…

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Saqr Alsakarneh, Internal Medicine Resident at University of Missouri–Kansas City in the US, as they discuss ‘Risk of De Novo Inflammatory Bowel Disease in Patients with Psoriasis and Psoriatic Arthritis Treated with IL-17A Inhibitors: A Population-Based Study’.…

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cyc…

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-T…

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

Join Professors Laura Coates and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis. They also give insights into th…

Join Professors Iain McInnes and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: effectiveness of JAKi compared with bDMARDs on pain reduction and effective second‑line b/tsDMARD for patients with rheumatoid arthritis unrespon…

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Phillip Helliwell, Professor of rheumatology at The University of Leeds in the UK, as they discuss ‘Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study’By The Immune-Mediated Inflammatory Disease Forum

Author Interview: Professor Phillip Helliwell, 2025 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate…

Join Professors Iain McInnes, Hans Bijlsma, and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: baricitinib dose reduction in patients with RA achieving sustained disease control and switching to bDMARDs vs cycling among JAKis…

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy …

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Denis McGonagle, Professor of investigative rheumatology at the NIHR funded Academic Unit for the Musculoskeletal Diseases and Leeds Teaching Hospitals NHS Trust in the UK, as they discuss his recent review ‘Subclinical psoriatic arthritis and disease interception—whe…

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, Professor McInnes discusses two papers: subgroups of patients with early RA with or without bDMARD who reached sustained DMARD-free remission and barriers to the widespread adoption of C…

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.…

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid a…

ACR 2024 Review Podcast by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conve…

Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitin…

Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmu…

ACR 2024 Highlights: Day 3 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

ACR 2024 Highlights: Day 2 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

ACR 2024 Highlights: Day 1 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

ACR 2024: Preview Podcast by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.By The Immune-Mediated Inflammatory Disease Forum

Join Professor Iain McInnes and Professor Leonard Calabrese for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the efficacy and safety of JAK inhibitors and TNF inhibitors for rheumatoid arthritis, while also u…

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Derin Karacabeyli of Arthritis Research Canada, a rheumatologist and resident in the University of British Columbia Clinician Investigator Program, as they discuss his recent paper ‘Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agon…

Webinar Highlights Podcast: Join Professor Christopher Ritchlin, and Professor Philip Mease as they discuss the recent webinar hosted on the IMID Forum ‘Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2’. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the sim…

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis invest…

Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.…

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.…

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.…

Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment respons…

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receiving guselkumab, focusing on disease control across domains and patient characteristics, and a systematic review and meta-analysis on genetic markers and…

Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the results of a Phase 3 trial on upadacitinib in nr-axSpA and the clinical outcomes of certolizumab pegol treatment in nr-axSpA stratified by base…

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the latest publication by Su, et al. and discuss the latest in bimekizumab therapy in PsA.By The Immune-Mediated Inflammatory Disease Forum

Join Professor Peter Nash from the Griffith University in Brisbane, and Blanca Hernández-Cruz, a rheumatologist at Virgen Macarena University Hospital in Seville, as they discuss her recent paper ‘Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic…

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-worl…

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the updated 2023 EULAR recommendations for PsA and the improvement of PROs reported in a Phase 2 trial with deucravacitinib.By The Immune-Mediated Inflammatory Disease Forum

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvement…

Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the long-term safety of ixekizumab as well as bimekizumab treatment in a TNFi-IR population.By The Immune-Mediated Inflammatory Disease Forum

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of …